Related Experiment Videos
Acral melanoma in Japan.
The Journal of Investigative Dermatology
|June 1, 1983
Summary
Malignant melanoma, particularly acral lentiginous melanoma, is increasing in Japan. This study reviewed 81 cases and 1597 literature cases, finding acral sites most common and survival rates at 35%.
Area of Science:
- Dermatology
- Oncology
- Pathology
Background:
- Malignant melanoma incidence and mortality rates have been rising globally.
- Acral melanomas, particularly on plantar surfaces, present unique diagnostic and therapeutic challenges.
- Understanding the epidemiology and clinicopathologic features of melanoma in specific populations is crucial for public health.
Purpose of the Study:
- To analyze the clinical and histologic characteristics of malignant melanoma in Japanese patients.
- To assess trends in malignant melanoma mortality and survival rates in Japan.
- To compare the features of acral melanomas in Japan with those reported internationally.
Main Methods:
- Retrospective review of clinical records and histologic materials from 81 malignant melanoma patients at Tohoku University School of Medicine.
- Statistical analysis of 1597 malignant melanoma cases from Japanese literature (1961-1982).
- Detailed clinicopathologic examination of acral melanoma cases.
Main Results:
- The annual mortality rate for malignant melanoma in Japan showed a near-linear increase over 20 years, reaching 0.21 per 100,000 in 1980.
- The five-year survival rate at Tohoku University was 35%.
- Acral sites, especially plantar surfaces, were the most common locations for melanoma. Clinicopathologic features of these acral melanomas were consistent with acral lentiginous melanoma observed in the United States.
Conclusions:
- Malignant melanoma represents a growing public health concern in Japan, with increasing mortality rates.
- Acral lentiginous melanoma is a significant subtype, sharing similar clinicopathologic features across different geographic regions.
- Further research and improved early detection strategies are warranted to improve survival rates for malignant melanoma.